Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (BCTX)
NASDAQ:BCTX
Total Valuation
BriaCell Therapeutics has a market cap or net worth of $17.08M. The enterprise value is $0.00.
Market Cap$17.08M
Enterprise Value$0.00
Share Statistics
BriaCell Therapeutics has 1,883,906 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,883,906
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BriaCell Therapeutics’s return on equity (ROE) is -1.48 and return on invested capital (ROIC) is -213.53%.
Return on Equity (ROE)-1.48
Return on Assets (ROA)-1.69
Return on Invested Capital (ROIC)-213.53%
Return on Capital Employed (ROCE)-2.14
Revenue Per Employee0.00
Profits Per Employee-1.66M
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BriaCell Therapeutics is ―. BriaCell Therapeutics’s PEG ratio is -0.00006.
PE Ratio―
PS Ratio0.00
PB Ratio0.17
Price to Fair Value0.17
Price to FCF-0.15
Price to Operating Cash Flow-0.61
PEG Ratio-0.00006
Income Statement
In the last 12 months, BriaCell Therapeutics had revenue of 0.00 and earned -36.50M in profits. Earnings per share was -86.25.
Revenue0.00
Gross Profit-147.89K
Operating Income-37.73M
Pretax Income-36.83M
Net Income-36.50M
EBITDA-36.63M
Earnings Per Share (EPS)-86.25
Cash Flow
In the last 12 months, operating cash flow was -31.91M and capital expenditures 0.00, giving a free cash flow of -31.91M billion.
Operating Cash Flow-31.91M
Free Cash Flow-31.91M
Free Cash Flow per Share-16.94
Dividends & Yields
BriaCell Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.29
52-Week Price Change-88.72%
50-Day Moving Average10.62
200-Day Moving Average21.11
Relative Strength Index (RSI)42.88
Average Volume (3m)71.25K
Important Dates
BriaCell Therapeutics upcoming earnings date is Mar 18, 2026, TBA (Confirmed).
Last Earnings DateDec 11, 2025
Next Earnings DateMar 18, 2026
Ex-Dividend Date―
Financial Position
BriaCell Therapeutics as a current ratio of 5.01, with Debt / Equity ratio of 0.00%
Current Ratio5.01
Quick Ratio5.01
Debt to Market Cap0.00
Net Debt to EBITDA0.29
Interest Coverage Ratio-735.71
Taxes
In the past 12 months, BriaCell Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BriaCell Therapeutics EV to EBITDA ratio is 0.17, with an EV/FCF ratio of 0.22.
EV to Sales0.00
EV to EBITDA0.17
EV to Free Cash Flow0.22
EV to Operating Cash Flow0.22
Balance Sheet
BriaCell Therapeutics has $10.18M in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.18M billion.
Cash & Marketable Securities$10.18M
Total Debt$0.00
Net Cash$10.18M
Net Cash Per Share$5.40
Tangible Book Value Per Share$40.53
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for BriaCell Therapeutics is $40.04, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$40.04
Price Target Upside347.32% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―